Literature DB >> 33627031

Content Analysis of U.S. Newspaper Coverage of Causes and Solutions to Vaping-Associated Lung Injury.

Olivia Algiers1, Yang Wang1, Linnea Laestadius1.   

Abstract

BACKGROUND: In 2019, an outbreak of vaping-associated lung injury (also known as "EVALI") spread throughout the U.S., linked to use of illicit THC cartridges. This paper examines U.S. newspaper coverage on the causes and solutions to EVALI.
Methods: A content analysis of 417 articles from April to December 2019 from two national newspapers, one regional newspaper, and the Associated Press was conducted. Articles were coded for information about EVALI causes, mentions of the brand Dank Vapes, calls for individuals take a specific action to prevent harm, and mentions of policy actions to address vaping. Mentions of increasing youth vaping and JUUL were also coded.
Results: Most articles (77%) provided an update on the number of EVALI cases and/or deaths. Fewer described EVALI symptoms (20%) or mentioned vaping cessation resources available to the public (2%). Almost half of articles also mentioned youth vaping as a concern (49%). Dank Vapes was mentioned rarely (4%) compared to JUUL (39%). After CDC recommendations changed to no longer recommend avoiding all vaping products, news articles became significantly less likely to mention nicotine products as a cause of EVALI or suggest that individuals cease all vaping. While policy was generally not articulated as a solution to EVALI, banning or limiting flavored nicotine vaping products were the most common policy actions mentioned. Conclusions/Importance: The discussions of causes of and solutions to EVALI were often intertwined with coverage of youth vaping, potentially failing to convey a clear sense of how the public should respond to the EVALI outbreak.

Entities:  

Keywords:  EVALI; e-cigarettes; lung injury; media analysis; vaping; youth vaping

Mesh:

Substances:

Year:  2021        PMID: 33627031     DOI: 10.1080/10826084.2021.1883663

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  6 in total

1.  Can social media monitoring help identify the next EVALI? An examination of Reddit posts about vitamin E acetate and Dank Vapes.

Authors:  Jessica K Pepper; Lauren V Zitney; Alexander Preiss; Thomas Bukowski; Glen Szczypka; Annice E Kim
Journal:  Drug Alcohol Depend       Date:  2021-11-25       Impact factor: 4.492

2.  Over 1 year later: smokers' EVALI awareness, knowledge and perceived impact on e-cigarette interest.

Authors:  Olivia A Wackowski; Stefanie Kristen Gratale; Michelle Jeong; Cristine D Delnevo; Michael B Steinberg; Richard J O'Connor
Journal:  Tob Control       Date:  2022-02-28       Impact factor: 6.953

Review 3.  Cannabis Vaping Among Youth and Young Adults: a Scoping Review.

Authors:  Melissa B Harrell; Stephanie L Clendennen; Aslesha Sumbe; Kathleen R Case; Dale S Mantey; Sunaina Swan
Journal:  Curr Addict Rep       Date:  2022-05-07

4.  Fundamentals of vaping-associated pulmonary injury leading to severe respiratory distress.

Authors:  Carolina Esquer; Oscar Echeagaray; Fareheh Firouzi; Clarissa Savko; Grant Shain; Pria Bose; Abigail Rieder; Sophie Rokaw; Andrea Witon-Paulo; Natalie Gude; Mark A Sussman
Journal:  Life Sci Alliance       Date:  2021-11-22

5.  Exposure to Negative News Stories About Vaping, and Harm Perceptions of Vaping, Among Youth in England, Canada, and the United States Before and After the Outbreak of E-cigarette or Vaping-Associated Lung Injury ('EVALI').

Authors:  Katherine East; Jessica L Reid; Robin Burkhalter; Olivia A Wackowski; James F Thrasher; Harry Tattan-Birch; Christian Boudreau; Maansi Bansal-Travers; Alex C Liber; Ann McNeill; David Hammond
Journal:  Nicotine Tob Res       Date:  2022-08-06       Impact factor: 5.825

6.  Analysis of state portrayals of the risks of e-cigarette use and the cause of the EVALI outbreak.

Authors:  Amanda Katchmar; Paul Shafer; Michael Siegel
Journal:  Harm Reduct J       Date:  2022-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.